INTRODUCTION
It is estimated that 1.5 million women living with HIV (HIVþ) are pregnant annually and in 2015, 77% received lifelong antiretroviral therapy (ART) or antiretroviral (ARV) prophylaxis for prevention of vertical HIV transmission during pregnancy, labor and delivery and postnatally during breastfeeding [1] . As global guidelines for universal treatment for pregnant women and, most recently, all individuals living with HIV are implemented, increasingly HIVþ women will either conceive on or initiate ART during pregnancy [2, 3] . The goal of finding an optimized, harmonized universal ART regimen for all people living with HIV, including pregnant and breastfeeding women, presents many individual and programmatic opportunities to ensure optimal health outcomes in pregnant women and further reduce vertical HIV transmission risk. Selection of an appropriate ART regimen in pregnancy requires consideration of regimen efficacy for maternal health and prevention of vertical HIV transmission, pregnancy pharmacokinetic (PK) changes as well as maternal and fetal safety. Considering that ARVs have been prescribed for pregnant women for more than two decades, the paucity of data relating to the efficacy and safety for pregnant women and their ARV-exposed children is striking [4] . We consider the current evidence related to dosing, efficacy and safety during pregnancy and breastfeeding of next-generation firstline and second-line ART regimens proposed for imminent introduction in the global marketplace
IMPORTANCE OF A MAXIMALLY SUPPRESSIVE REGIMEN FOR MATERNAL HEALTH AND PREVENTION OF VERTICAL TRANSMISSION
In 2015, the health and survival benefits of early ART initiation for HIVþ adults with CD4 cell counts more than 500 cells/mm 3 were established [5 && ,6 && ]. Multiple studies have demonstrated that ARVs to the mother (and/or infant) throughout the entire period of vertical HIV transmission risk (pregnancy, delivery and the duration of breast feeding) are critical to prevent new infant infections [7,8 && , 9-11] . The Promoting Maternal and Infant Survival Everywhere (PROMISE) trial recently finally provided randomized trial evidence for the beneficial effect on early vertical HIV transmission of maternal ART initiated during pregnancy compared to zidovudine (ZDV) prophylaxis in women with high CD4 cell counts [12 && ]. The French Perinatal Cohort (EPF) demonstrated that women on ART preconception have the lowest risk of perinatal HIV transmission, with increasing risk of transmission by each advancing trimester of ART initiation [8 && ]. In addition, independent of timing of ART initiation, HIV viral load at delivery of 50-400 copies/ml was associated with a four-fold greater odds [95% confidence interval (CI) 1.9-8.2] of vertical HIV transmission compared with viral load less than 50 copies/ml [8 && ]. Undergoing an ART regimen change during pregnancy, shorter duration on ART and height of pre-ART viral load have all been associated with viral nonsuppression at the end of pregnancy [13, 14] . Furthermore, CD4 cell counts may not be adequately sensitive to identify viral nonsuppression and pregnant women at highest risk of vertical HIV transmission [15] . The need to switch ART regimens during pregnancy to avoid maternal or fetal adverse events can jeopardize maternal and infant health outcomes and is counter to the goal of an optimized, harmonized universal ART regimen. Having a universal, highly potent and safe ART regimen for all individuals living with HIV in low-income and middle-income countries (LMICs) including pregnant women is clearly the most beneficial strategy to keep HIVþ mothers alive and healthy and to prevent transmission of HIV to their children.
As the universal ART strategy expands, the incidence of horizontally and vertically acquired HIV infection is expected to decline further. However, a rising prevalence of transmitted HIV drug resistance in LMIC is a concern, particularly resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) [16] . Issues related to drug resistance, drug efficacy and ARV regimens are addressed elsewhere in this issue [17, 18] . The implications of this for vertical HIV transmission are unclear. Perinatal transmission of resistant virus is unusual and previous reports have shown that in the presence of mixed resistant and wild-type virus populations in the mother, only wild-type and not resistant virus was vertically transmitted [19] .
UNIVERSAL ART REGIMENS: CONSIDERATIONS FOR PREGNANT AND BREASTFEEDING WOMEN

Pregnancy pharmacokinetic considerations
Pregnancy results in dramatic physiologic alterations that may impact on drug disposition, including absorption, distribution and elimination [20] . Even with substantial pregnancy-induced changes to drug metabolism, ARV exposure adequate to achieve viral suppression is most often reached, with the exception of boosted-protease inhibitors (Table 1) [21,22 && ]. Nucleos(t)ide reverse transcriptase inhibitors (NRTIs), including FTC, 3TC and TDF, undergo increased renal elimination during pregnancy due to elevated renal blood flow and glomerular filtration particularly during the third trimester [22 && ]. Despite demonstrated increased clearance, pregnant women still met drug exposure targets for FTC, 3TC and TDF comparable to that during the postpartum period or in nonpregnant adults [23] [24] [25] [26] [27] [28] 29 & ]. NRTIs,
KEY POINTS
The global market is poised to introduce several new ARV medications to optimize HIV treatment outcomes.
Several issues need to be considered regarding the use of these medications in pregnant and breastfeeding women.
Pregnancy pharmacokinetic considerations include potentially insufficient efavirenz exposure if dosed at 400 mg/day, the need for twice daily darunavir dosing and the paucity of data related to tenofovir alafenamide and dolutegravir dosing, safety and efficacy.
The potential for adverse pregnancy and birth outcomes needs to be assessed and monitored. Optimized antiretroviral drugs for pregnant women Slogrove et al.
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www.co-hivandaids.comincluding FTC, 3TC and TDF, rapidly cross the placenta, with cord-to-maternal-blood ratios more than 1 [23,25,29 & ]. This has theoretical advantages for fetal preexposure prophylaxis, but also greater potential for negative fetal, infant and life-course effects. There are currently no PK data on TAF in pregnant women to inform appropriate pregnancy dosing or safety, however, studies are planned.
With standard dosing of EFV (600 mg/day), pregnancy trough concentrations are reduced due to increased metabolism by hepatic cytochrome P450 (CYP450) enzymes that are induced by elevated progesterone during pregnancy [21,22 && ,30,31] . Despite this, 88% of pregnant women remained within the therapeutic range for EFV in the third trimester [30] . EFV crosses the placenta, but less well than the NRTIs, with cord-to-maternal-blood ratios of 0.5 [30] . Pharmacokinetic studies of lower dose EFV (400 mg/day) are currently underway in pregnant women. Considering pregnancy-induced increased EFV metabolism, these studies are critical to be certain that EFV 400 still meets the required exposure targets to achieve viral suppression during pregnancy.
As a result of pregnancy-induced CYP450 enzyme induction, the standard adult dose of ritonavir (RTV)-boosted DRV (DRV/r) of 800 mg/100 mg daily results in inadequate DRV exposure during the third trimester [21,32
A twice daily dose of DRV/r (600 mg/100 mg) is recommended instead, and although this dose also results in reduced exposure during the third trimester compared to postpartum, it is thought to be adequate [34] . An increased dose of 800 mg twice daily does not result in improved DRV exposure and is not recommended in pregnant women [35 & ]. Protease inhibitors cross the placenta poorly, with the possible advantage of having fewer negative effects for the fetus, but are therefore not suitable agents for fetal preexposure prophylaxis.
Like NNRTIs and protease inhibitors, integrase strand transfer inhibitors (INSTIs), including DTG, raltegravir (RAL) and elvitegravir (EVG), undergo metabolism by the CYP450 enzymes. PK data on DTG use in pregnancy are limited to a single study demonstrating reduced DTG exposure during the third trimester compared to postpartum measurements in the same women [36 && ]. Third trimester exposure was similar though to nonpregnant historic controls and adequate viral suppression was achieved in all 15 women [36 && ]. EVG/cobicistat exposure was substantially lower during pregnancy than postpartum and only 75% (14 of 19) of women were virologically suppressed at delivery [37] . RAL is known to readily cross the placenta [38, 39] [40, 41] . This raised caution that monitoring for acquisition of viral resistance is warranted in the rare HIV-infected child exposed to FTC or 3TC via breast milk [41, 42] . TDF and EFV occur at much lower levels in breast milk resulting in negligible exposure to the breastfeeding infant [41, 43] .
Although there are no data on breast milk passage of DRV, lopinavir (LPV) has been observed to have very low to undetectable levels in breast milk [44, 45] . There are no data on breast milk excretion of INSTIs.
CONSIDERATIONS FOR IN-UTERO ANTIRETROVIRAL EXPOSED CHILDREN
Teratogenicity
Drug exposure during critical early stages of embryonic development poses the potential for teratogenicity and development of congenital anomalies. Of all ARVS, EFV has presented the most concern regarding teratogenic potential as animal studies in conjunction with isolated human case-reports raised the possibility of neural tube defects with first trimester EFV exposure [46] . With time, the accumulating evidence has been reassuring that first trimester EFV exposure poses no additional risk compared with second or third trimester exposure for congenital anomalies in general or for central nervous system defects specifically [47, . Similarly, the French EPF has observed no association between overall birth defects and first trimester exposure to FTC, TDF, LPV or RTV [49] . The EFP has not yet reported on DRV, DTG or TAF exposures.
Birth outcomes
HIVþ compared to HIV-negative women experience high rates of adverse birth outcomes including stillbirth, preterm birth (PTB), low birth weight (LBW) . Similarly, in the United Kingdom and Ireland, women on NNRTI-based regimens at conception had a lower probability of PTB compared to women on protease inhibitor-based regimens [57] .
In the PROMISE trial that established the superiority of maternal ART over ZDV monotherapy for prevention of vertical HIV transmission among immunocompetent women, significantly more maternal adverse events and adverse birth outcomes occurred in both the ZDV-based (ZDVþ3TCþLPV/r) and TDF-based (TDFþFTCþLPV/r) ART arms compared to ZDV alone [12 && ]. Furthermore, TDF-based ART was associated with significantly higher rates of severe adverse birth outcomes than ZDV-based ART (9.2 versus 4.3%, P ¼ 0.02) and specifically a higher rate of very preterm delivery before 34 weeks (6.0 versus 2.6%, P ¼ 0.04), with significantly more neonatal deaths in the first week of life (4.4 versus 0.6%, P ¼ 0.001). The authors hypothesized that pharmacologic interactions between TDF and LPV/r in pregnant women could have been responsible for the increase in severe adverse pregnancy outcomes in the TDF-based ART arm [12 && ].
Life course effects of perinatal antiretroviral exposure
There are indications that long-term consequences may result from fetal ARV exposure. There has been evidence for some time of genotoxicity and mitochondrial toxicity in infants following NRTI exposure [58 && ]. The clinical significance of these observations is unclear but has potential for poorer neurodevelopmental outcomes and myocardial aberrations [59, 60] . More recently, genotoxicity, specifically aneuploidy and altered gene expression in DNA repair and telomere maintenance pathways, has been recognized in infants with in-utero exposure to ZDV or TDF [61 ] . It is unknown whether these genotoxic signatures persist, however, they may represent predisposing factors for an oncogenic event and possibly later cancer [61 & ]. Reassuringly, an updated analysis from the EPF, including 15,163 HIV-exposed uninfected (HEU) children exposed to at least one NRTI in utero, did not observe an increased risk of childhood cancer compared to the general population following any NRTI exposure [standardized incidence ratio 0.8 (95% CI 0.47-1.24)] or specifically following exposure to TDF, FTC or TDF and FTC in combination [62 && ]. Didanosine (ddI), however, was associated with an elevated hazard for childhood cancer with first trimester compared to no ddI exposure [hazards ratio 5.5 (95% CI 2.1-14.4)] [62 && ]. Although ddI has been replaced with safer and less toxic drugs, these findings do emphasize the need for systematic long-term surveillance of children and adults exposed in utero to ARVs.
Although there has been concern about in-utero exposure to TDF specifically and its effects on the developing fetal skeletal structure, in two large US-based cohorts there was no evidence of an association between in-utero TDF exposure and fetal growth [63, 64] . However, lower length-forage Z-score in TDF-exposed infants at age 1 year and a lower weight-for-age Z-score at 6 months of Optimized antiretroviral drugs for pregnant women Slogrove et al. age were observed [63, 64] . In Ugandan and Zimbabwean infants exposed to TDF in utero, there was no evidence of inferior growth at age 2 years compared to HIV-exposed infants not exposed to TDF [65] . Furthermore, in a South African study, there was no association with duration of TDF-exposure as part of an EFV-based regimen and fetal or postnatal length growth to 12 months of age [66, 67] . Significantly, lower newborn bone mineral content has been described following late pregnancy TDF exposure compared to no TDF exposure in HIV-exposed newborns [68 & ]. The long-term importance of these observations remains uncertain but highlights the need for further surveillance of TDF-exposed infants. With the lower renal toxicity profile of TAF, it would be expected to have a lower potential for renal and bone toxicity following in-utero exposure; however, this is yet to be studied.
In addition, HEU children appear to experience immune system differences, an increase in infectious disease severity and greater mortality compared to HIV-unexposed children [69] [70] [71] . Early studies suggested an association with advanced maternal HIV disease [72, 73] ; however, more recent evidence indicates that these findings persist despite improving maternal health and safer breastfeeding in the context of maternal ART [71, 74, 75] . The role of specific ARVs or ART more generally in ameliorating or exacerbating this increased morbidity and mortality is unclear, and further work to understand the risks to HEU child health in the current context of new ART regimens is required [76] .
CONCLUSION
Having a universal, highly potent and safe ART regimen for all individuals living with HIV in LMIC including pregnant women is clearly the most beneficial strategy to keep HIVþ mothers alive and healthy and to prevent transmission of HIV to their children. As the global community prepares to introduce optimized ART regimens in LMIC, special considerations for pregnant and breast feeding women take on increased importance. Pharmacokinetic considerations include potentially insufficient EFV exposure if dosed at 400 mg/day, the need for twice daily DRV dosing and the paucity of data related to TAF and DTG dosing, safety and efficacy during pregnancy. Furthermore, while the benefit of ART during pregnancy is clear, it does not come without a price. Increasingly evidence suggests an association with adverse birth outcomes, particularly in women conceiving on ART, and with varying risk by drug and drug combination. Whether there is potential for long-term harm incurred with these exposures also remains to be Adapted from [77] .
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determined. There are a number of clinical trials and studies in progress or planned that aim to determine dosing, safety and efficacy of several of the new ARVs and ARV combinations (Table 2 ) [77] . These studies will provide crucial evidence to inform global guidance and to determine the safe use of these drugs among pregnant and breast feeding women. It will have to be determined whether the use of this next generation of optimized ARVs will also optimize health outcomes of pregnant women and their children.
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